Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 ± albumin-bound paclitaxel in triple-negative breast cancer
CTR20190197Phase 2Completed
- Sponsor
- Alphamab Oncology
- Start
- Apr 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in triple-negative breast cancer (TNBC), sponsored by Alphamab Oncology. Started Apr 2019; status: completed.
02
Drugs
erfonrilimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20190197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190197.